Management of first‐line palliative chemotherapy for post‐treatment metastasis after gemcitabine plus cisplatin induction chemotherapy: Gemcitabine plus cisplatin and non‐gemcitabine plus cisplatin chemotherapy

Abstract

Background To evaluate whether patients with post‐treatment metastasis are suitable for GP first‐line palliative chemotherapy (PCT) after undergoing GP IC. Methods Seven hundred and forty‐six patients with post‐treatment metastasis after undergoing GP IC were eligible. Survival outcomes were compared. Results Significant differences in survival rates were observed between patients treated with GP and non‐GP chemotherapy (2‐year progression‐free survival [PFS]: 0.7% vs. 9.7%). We investigated survival outcomes of patients treated with GP PCT within 2 years after undergoing GP IC, treated with GP PCT 2 years after undergoing GP IC, and those of non‐GP PCT patients (2‐year PFS: 0.0%, 2.3%, 9.7%). However, there was no difference in the 2‐year PFS between the patients that received GP PCT 2 years after undergoing GP IC and the non‐GP PCT treated patients. Conclusions GP is not recommended for patients that have received GP IC within 2 years. Two years after undergoing GP IC, GP can be considered.